Search results for "hepatitis c rna"

showing 1 items of 1 documents

Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM.

2020

Abstract Background In Europe, increases in HCV infection have been observed over the last two decades in MSM, making them a key population for recently acquired HCV. Alternative combinations of direct-acting antiviral agents against early HCV infection need to be assessed. Patients and methods In this pilot trial, MSM with recently acquired genotype 1 or 4 HCV infection were prospectively included and received 8 weeks of oral grazoprevir 100 mg and elbasvir 50 mg in a fixed-dose combination administered once daily. The primary endpoint was sustained virological response evaluated 12 weeks after the end of treatment (EOT) (SVR12). Secondary endpoints were the virological characterization of…

hepatitis C virusCyclopropanesMaleadverse eventmen who have sex with menHepacivirusmedicine.disease_causeSexual and Gender Minoritiesblood HIV RNA0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesfollow-upClinical endpointMedicinePharmacology (medical)infections030212 general & internal medicinehepatitis ceducation.field_of_studySulfonamideshepatitis c rnaImidazolesvirus diseasesHepatitis Cvirologyhepatitis C virus genotype 13. Good healthEuropeInfectious DiseasesGrazoprevirRNA Viral030211 gastroenterology & hepatologyDrug Therapy CombinationMicrobiology (medical)medicine.medical_specialtyElbasvirGenotypeHepatitis C virusPopulationelbasvirAntiviral Agentsreinfection03 medical and health sciencesInternal medicineQuinoxalinesHumansHomosexuality MaleAdverse effecteducationplasmasuicideBenzofuransPharmacologybusiness.industrySurrogate endpointHIVgrazoprevirHepatitis C Chronicmedicine.diseaseAmidessurrogate endpoints[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyQuality of LifeCarbamatesbusinessThe Journal of antimicrobial chemotherapy
researchProduct